Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 4Rectal Neoplasms 2Cirrhosis, Familial, with Pulmonary Hypertension 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pathologic Complete Response 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Esophageal Neoplasms 1Colorectal Cancer With Liver Metastasis 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 7Cisplatin 6Oxaliplatin 5Fluorouracil 4lenvatinib 3envafolimab 3S 1 (combination) 3Capecitabine 3toripalimab 2pembrolizumab 2Leucovorin 2Irinotecan 2Folfox protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1surufatinib 1pertuzumab 1mitazalimab 1durvalumab 1disitamab vedotin 1camrelizumab 1anlotinib 1Simvastatin 1Self Expandable Metallic Stents 1Bevacizumab 1Albumin-Bound Paclitaxel 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Biliary Tract Neoplasms × Folfox protocol × Clear all
NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Fudan University

Phase 2 Not yet recruiting
74 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡